Joined: Fri Aug 11, 2006 1:46 pm
Location: SF Bay Area (Northern CA)
Namenda improves quality of life in PDD+DLB
This is a small study performed by some European LBD experts. The authors already published a related study indicating that Namenda is effective in treating PDD and DLB. The current study evaluated what effect Namenda has on quality of life in PDD (Parkinson's Disease Dementia) and DLB (Dementia with Lewy Bodies). The authors believe this is the first study that looked at how pharmacological intervention affects quality of life. They think looking at quality of life is important: "QOL measurements direct attention to many important aspects of living with a chronic neurodegenerative disease that cannot be portrayed using merely cognitive and functional rating scales."
Patients in Sweden, Norway, and the UK with PDD and DLB were given either Namenda over a 24 week period or they were given a placebo. The caregivers of those who got the Namenda reported that the quality of life, particularly aspects related to body functions, was improved over the 24-week treatment period.
In the Discussion section, the authors speculate: "...the low QOL reported in DLB could primarily be an effect of the organic disease affecting the physical functions. This would mean that measures taken to improve body functions, including activities of daily living, may also enhance overall impression of QOL."
This paragraph on Alzheimer's caregivers rating quality of life is interesting: "Previous studies on AD patients have noted a discrepancy between patient- and caregiver-rated QOL. Patients with AD tend to rate their QOL higher than their caregivers, which was explained by some authors as being due to the cognitive deficit of the patient causing a lack of insight into his or her disease state. Others highlight that the lower informant ratings are merely a reflection of the caregiversâ own circumstances, and that the distress of or burden on the caregiver may have influenced the perception of QOL in the patient."
I've copied the short abstract below.
Dementia and Geriatric Cognitive Disorders. 2011 Nov 25;32(4):227-234. [Epub ahead of print]
Quality of Life and the Effect of Memantine in Dementia with Lewy Bodies and Parkinson's Disease Dementia.
Larsson V, Engedal K, Aarsland D, Wattmo C, Minthon L, Londos E.
Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, MalmÃ¶, Sweden.
Aim: To investigate quality of life (QOL) and the effect of memantine treatment in patients with Lewy body dementias.
Methods: A secondary analysis of a randomized controlled study in 70 patients with Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB) over 24 weeks using caregiver-rated QOL-Alzheimer's disease (AD) in domains according to the WHO's classification of health.
Results: Baseline QOL shows lower ratings for body functions over environmental factors in DLB/PDD. Treatment with memantine significantly improves life as a whole compared to placebo and improves total QOL, body function and structure.
Conclusion: This study shows that memantine improves QOL in Lewy body dementias. We also demonstrate important QOL patterns which can be used in clinical practice.
Copyright Â© 2011 S. Karger AG, Basel.
PubMed ID#: 22122992